source
- FDA delays decision on Belite Bio's Stargardt disease drug to May 12The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…
- Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football playersResearchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…